Mazdutide Placebo

Phase 3

HHuijie Zhang

Mazdutide Placebo is one of 7 therapeutic programs targeting Diabetic Kidney Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Diabetic Kidney DiseaseNot yet recruiting

Diabetic Kidney DiseasePhase 3

Not yet recruiting

Competition

Competitive Landscape

8 competitors in Diabetic Kidney Disease

#DrugCompanyPhaseTrials

Kerendia

Bayer

Approved

2 2

Jardiance

Boehringer Ingelheim

Approved

2 3

Mazdutide

Eli Lilly

Phase 3

1 4

Angiotensin Receptor Blocker

NNational University of Ireland, Galway, Ireland

Phase 3

1 5

Mazdutide Placebo

HHuijie Zhang

Phase 3

1 6

R3R01

RRiver 3 Renal Corp.

Phase 2

1 7

AP303 150μg

AAlebund Pharmaceuticals

Phase 1

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

ApprovedNot yet recruiting

Diabetic Kidney Disease

NCT07775846

Clinical

Trials by Indication[1]

Diabetic Kidney Disease1 trial

QUAdruple Therapy With RASi, Empagliflozin, Finerenone, and Mazdutide in Type 2 Diabetes and Early Treatment of Nephropathy(QUARTET-DKD)

Not yet recruiting·HHuijie Zhang·Approved·NCT07775846·820 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Mazdutide Placebo. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Mazdutide Placebo. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Huijie Zhang company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: HHuijie Zhang

Mazdutide Placebo

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Diabetic Kidney Disease1 trial

References

Drug Info

Quick Facts

Related News